Idorsia Ltd (IDIA) Price & Analysis

Compare

10 Followers

IDIA Stock Chart & Stats

CHF3.74

-CHF0.05(-3.98%)

At close: Mar 06 4:00 PM EST

CHF3.74

-CHF0.05(-3.98%)

Day’s Range― - ―

52-Week RangeCHF0.65 - CHF4.85

Previous CloseN/A

Volume178.76K

Average Volume (3M)2.48M

Market Cap

CHF922.59M

Enterprise ValueCHF0.00

Total Cash (Recent Filing)CHF71.20M

Total Debt (Recent Filing)CHF1.26B

Price to Earnings (P/E)―

Beta2.39

Next Earnings

Feb 26, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding250,736,040

10 Day Avg. Volume2,649,008

30 Day Avg. Volume2,478,790

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)-0.12

Price to Sales (P/S)1.33

P/FCF Ratio-0.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF5.25

Price Target Upside40.37% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengtheningProceeds from recent equity financing strengthen the balance sheet and provide funding to accelerate commercialization efforts and further advance a risk‑mitigated pipeline.

Clinical Differentiation And Renal BenefitClinical evidence showing meaningful blood pressure reductions, favorable tolerability, and marked reductions in albuminuria positions the therapy as a differentiated option for patients with uncontrolled hypertension and chronic kidney disease.

Commercial Partnership PotentialHealth Canada marketing authorization for aprocitentan enhances the drug's attractiveness to potential North American commercial partners, supporting pursuit of regional deals that could broaden patient access.

Bears Say

Equity Dilution And Funding RiskPotential near‑ to medium‑term equity dilution creates shareholder value risk and could pressure the stock if additional capital is required.

Late‑stage Clinical Failure RiskFailure of late‑stage drug candidates in pivotal trials would materially weaken pipeline value and could trigger downward revisions to forecasts.

Regulatory Approval UncertaintyInability to secure timely regulatory approvals for key assets could delay market entry and limit near‑term revenue prospects.

Idorsia Ltd News

Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, with...

10d ago

Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd and keeping the price target...

1M ago

Idorsia upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux upgraded Idorsia (IDRSF) to Buy from Hold with a CHF 4.50 price target The firm sees...

1M ago

Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Idorsia Ltd today and set a price target...

3M ago

Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, with...

4M ago

Idorsia upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju upgraded Idorsia (IDRSF) to Buy from Neutral with a price target of CHF...

4M ago

Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Idorsia (IDRSF) to CHF 2 from CHF 1 and keeps...

5M ago

Idorsia Ltd Earnings Call: Strong Growth Amid Challenges

Idorsia Ltd (($CH:IDIA)) has held its Q2 earnings call. Read on for the main highlights of the call....

6M ago

IDIA FAQ

What was Idorsia Ltd’s price range in the past 12 months?

Idorsia Ltd lowest stock price was CHF0.65 and its highest was CHF4.85 in the past 12 months.

What is Idorsia Ltd’s market cap?

Idorsia Ltd’s market cap is CHF922.59M.

When is Idorsia Ltd’s upcoming earnings report date?

Idorsia Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 42 days.

How were Idorsia Ltd’s earnings last quarter?

Idorsia Ltd released its earnings results on Oct 30, 2025. The company reported -CHF0.275 earnings per share for the quarter, missing the consensus estimate of -CHF0.22 by -CHF0.055.

Is Idorsia Ltd overvalued?

According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Idorsia Ltd pay dividends?

Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here

What is Idorsia Ltd’s EPS estimate?

Idorsia Ltd’s EPS estimate is -0.2.

How many shares outstanding does Idorsia Ltd have?

Idorsia Ltd has 250,736,040 shares outstanding.

What happened to Idorsia Ltd’s price movement after its last earnings report?

Idorsia Ltd reported an EPS of -CHF0.275 in its last earnings report, missing expectations of -CHF0.22. Following the earnings report the stock price went down -1.63%.

Which hedge fund is a major shareholder of Idorsia Ltd?

Currently, no hedge funds are holding shares in CH:IDIA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd (IDIA) Earnings & Revenues

Historic Earnings Reports

IDIA Stock 12 Month Forecast

Average Price Target

CHF5.25

▲(40.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"CHF1","3":"CHF3","5":"CHF5","7":"CHF7","-1":"-CHF1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF5.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF4.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.255,4.389230769230769,4.523461538461539,4.657692307692308,4.7919230769230765,4.926153846153846,5.060384615384615,5.194615384615385,5.328846153846154,5.4630769230769225,5.597307692307693,5.731538461538461,5.865769230769231,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.255,4.331538461538462,4.408076923076923,4.484615384615385,4.561153846153846,4.637692307692308,4.7142307692307694,4.7907692307692304,4.867307692307692,4.943846153846154,5.020384615384615,5.096923076923077,5.173461538461538,{"y":5.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.255,4.273846153846153,4.292692307692308,4.311538461538461,4.330384615384616,4.349230769230769,4.368076923076923,4.386923076923077,4.405769230769231,4.424615384615384,4.443461538461539,4.462307692307692,4.4811538461538465,{"y":4.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.822,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.704,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.648,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.465,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.639,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.255,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >